CHAIN Biotechnology Ltd was founded in 2014 to develop new Clostridium-based microbial products for high value human healthcare.
The Company has developed a novel delivery platform for live biotherapeutic products (LBPs) to treat chronic gut-related diseases where no effective treatments exist today such as Inflammatory Bowel Disease.
CHAIN’s delivery platform has been enhanced using advanced synthetic biology and exemplified through the production of short-chain fatty acids like (R)-3-hydroxybutyrate. The delivery platform also supports a product pipeline including specific therapeutic peptides.
CHAIN’s new class of biotherapeutic is transformative, offering more effective and affordable treatment for chronic disease.
– Dr Edward Green, Chief Executive